$134.49▴ 0.19%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-234.54MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Apogee Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit.
Key numbers
Valuation
EPS (TTM)$-4.33
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$0.00
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days5 articles
4 bullish0 neutral1 bearish
Why Wall Street Can't Get Enough of This Dividend King
3 Reasons to Buy AbbVie Stock Like There's No TomorrowHalper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
What This Apogee Insider Move Might Mean After a 247% Stock Run
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.